目的:探讨对肝硬化门脉高压症进行综合治疗所取得的临床效果。方法:选择2012年4月-2013年6月曾在我院进行治疗的肝硬化门脉高压症患者96例,将这些患者随机分为数量相等的两组,并将这两组患者分别记作观察组与对照组,观察组患者利用奥曲肽联合美托洛尔方法进行治疗,对照组患者单纯以美托洛尔进行治疗,观察两组患者的临床治疗效果,并进行比较分析。结果:在结束治疗之后,对两组患者的临床治疗效果进行观察,两组患者的临床症状均得到一定程度改善,但观察组中患者的治疗效果明显优秀于对照组,两组患者之间有显著差异存在;观察两组患者的并发症发生率,观察组中患者的并发症发生率为8.3%,对照组中患者的并发症发生率为20.8%,两组患者之间有显著差异存在。结论:对于肝硬化门脉高压症,利用奥曲肽联合美托洛尔方法对其进行综合治疗,能够取得较好的临床治疗效果,能够使患者的临床症状得到明显改善,并且并发症的发生率比较低,在肝硬化门脉高压症的治疗方面有着积极作用,可进行广泛推广应用。 Objective: To explore the clinical effect of comprehensive treatment of cirrhosis and portal hypertension. Methods: A total of 96 patients with cirrhosis and portal hypertension who were treated in our hospital from April 2012 to June 2013 were selected and randomly divided into two equal groups, and the two groups were recorded as The observation group and the control group, the observation group were treated with octreotide combined with metoprolol. The control group patients were treated with metoprolol alone. The clinical effects of the two groups were observed and compared. Results: After the end of treatment, the clinical effects of two groups of patients were observed, the clinical symptoms of both groups have been improved to some extent, but the observation group, the treatment effect was significantly better in the control group, between the two groups of patients Significant differences exist; the incidence of complications was observed in two groups of patients, the incidence of complications in the observation group was 8.3%, the incidence of complications in the control group was 20.8%, there were significant differences between the two groups of patients. Conclusion: For patients with cirrhosis and portal hypertension, the combination of octreotide and metoprolol can improve the clinical symptoms and improve the clinical symptoms of the patients with cirrhosis and metoprolol, and the complication rates are compared Low, in the treatment of cirrhosis and portal hypertension has a positive effect, can be widely promoted.